SCHEMBL30543749

SCHEMBL30543749

Cc1cc(Nc2cc(C(F)(F)F)ccc2N)on1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.38
▸ MAPT P10636 3/20 0.38
▸ GAA P10253 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ GFER P55789 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ EDNRA P25101 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ EPHX2 P34913 2/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ TYK2 P29597 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ CFTR P13569 1/20 0.35
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC8 Q9BY41 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18193377 1.00 ALDH1A1 (0.38) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL17586644 0.81 EDNRA (0.42) ALDH1A1MAPTGAAKDM4EL3MBTL1
SCHEMBL17582873 0.78 AKR1B1 (0.50) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL16061453 0.74 EDNRA (0.43) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL30167000 0.70 ALDH1A1 (0.46) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL118960 0.70 ALDH1A1 (0.46) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL17481366 0.69 EDNRA (0.42) ALDH1A1KDM4EEDNRASMN1; SMN2EPHX2
SCHEMBL19661475 0.67 ALDH1A1 (0.46) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL112521 0.66 LMNA (0.56) ALDH1A1MAPTGAAKDM4EMEN1
SCHEMBL378246 0.66 ALDH1A1 (0.52) ALDH1A1MAPTGAAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351559-B2 Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators BIOHAVEN THERAPEUTICS LTD. (VG) 2025-07-08 — — US disclosed
US-20240300903-A1 BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2024-09-12 — — US disclosed
EP-4289822-A2 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (US) 2023-12-13 — — EP disclosed
EP-3572405-B9 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD (US) 2023-12-06 — — EP disclosed
US-11834418-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators BIOHAVEN THERAPEUTICS LTD. (VG) 2023-12-05 — — US disclosed
EP-3572405-B1 BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2023-07-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834418-B2 Benzoimidazol-1,2-yl amides as Kv7 channel activators KCNA7, KCNJ2, KCNK17 ALDH1A1 2106/4885MAPT 2988/4885GAA 1804/4885
US-20240300903-A1 BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNK17, KCNK2 ALDH1A1 1492/4885MAPT 2817/4885GAA 2240/4885
US-12351559-B2 Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators KCNA7, KCNJ2, KCNK17 ALDH1A1 2065/4885MAPT 2655/4885GAA 1840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback